Arsenic Trioxide & Tyrosine Kinase Inhibitors for Chronic Myelogenous

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Completed	`NCT02592447` - Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention	N/A
Withdrawn	`NCT04282174` - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies	Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Withdrawn	`NCT01011998` - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)	Phase 2
Completed	`NCT00378534` - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants	Phase 2
Completed	`NCT00098033` - Investigation of Clofarabine in Acute Leukemias	Phase 2
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Completed	`NCT02581007` - Reduced Intensity Conditioning Transplant Using Haploidentical Donors	Phase 2
Terminated	`NCT03547154` - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)	Phase 2/Phase 3
Terminated	`NCT02709083` - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia	Phase 2
Terminated	`NCT02145039` - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	N/A
Terminated	`NCT02146846` - Population Pharmacokinetics of Imatinib in CML Patients in Iran	N/A
Active, not recruiting	`NCT01036009` - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies	Phase 2
Completed	`NCT00990587` - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy	Phase 1
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Terminated	`NCT00500006` - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)	Phase 1
Completed	`NCT00493181` - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients	Phase 2
Completed	`NCT00081926` - Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Phase 4

NCT number	NCT01397734
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Terminated
Phase	Phase 1
Start date	September 2011
Completion date	August 6, 2018

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms